Michela Meregaglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7225214/publications.pdf

Version: 2024-02-01

687363 752698 21 406 13 20 citations h-index g-index papers 21 21 21 783 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Social Science and Medicine, 2022, 292, 114519.	3.8	29
2	Consideration of quality of life in the health technology assessments of rare disease treatments. European Journal of Health Economics, 2022, 23, 645-669.	2.8	7
3	Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms. PharmacoEconomics - Open, 2022, , 1.	1.8	O
4	The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. Patient, 2021, 14, 485-503.	2.7	31
5	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. Journal of Clinical Epidemiology, 2021, 136, 26-36.	5.0	17
6	The estimation of health state utility values in rare diseases: overview of existing techniques. International Journal of Technology Assessment in Health Care, 2020, 36, 469-473.	0.5	8
7	â€~Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases. Pharmacoeconomics, 2020, 38, 557-574.	3.3	14
8	A scoping review of core outcome sets and their †mapping†onto real-world data using prostate cancer as a case study. BMC Medical Research Methodology, 2020, 20, 41.	3.1	13
9	Low socioâ€economic conditions and prematurityâ€related morbidities explain healthcare use and costs for 2â€yearâ€old very preterm children. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1791-1800.	1.5	3
10	Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. European Journal of Health Economics, 2019, 20, 181-193.	2.8	14
11	The short-term economic burden of gestational diabetes mellitus in Italy. BMC Pregnancy and Childbirth, 2018, 18, 58.	2.4	28
12	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. European Journal of Cancer, 2018, 93, 89-98.	2.8	14
13	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. Value in Health, 2017, 20, 799-808.	0.3	15
14	Mudâ€Bath Therapy in Addition to Usual Care in Bilateral Knee Osteoarthritis: An Economic Evaluation Alongside a Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 966-972.	3.4	34
15	A systematic literature review of health state utility values in head and neck cancer. Health and Quality of Life Outcomes, 2017, 15, 174.	2.4	34
16	A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. ClinicoEconomics and Outcomes Research, 2016, 8, 267.	1.9	22
17	Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clinical Drug Investigation, 2016, 36, 177-194.	2.2	51
18	Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. PLoS ONE, 2015, 10, e0123383.	2.5	39

#	Article	IF	CITATIONS
19	Hospital Burden and Gastrointestinal Surgery in Inflammatory Bowel Disease Patients in Italy: A Retrospective Observational Study. Journal of Crohn's and Colitis, 2015, 9, 853-862.	1.3	15
20	Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 913-929.	1.4	17
21	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients Journal of Clinical Oncology, 2015, 33, TPS6625-TPS6625.	1.6	1